Skip to content
Screener

Alumis Inc. ALMS Accrued Research And Development Current

Accrued Research And Development Current at other companies

Relmada Therapeutics, Inc. logo
Relmada Therapeutics, Inc.RLMD
$1.82M-29.1%
Assembly Biosciences logo
Assembly BiosciencesASMB
$1.54M-27.0%
Roivant Sciences logo
Roivant SciencesROIV
$113.44M+128%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$98M+60.7%
Lantheus Holdings logo
Lantheus HoldingsLNTH
$12M+31.3%
Lantheus Holdings logo
Lantheus HoldingsLNTH
$12M+31.3%

Other financials

Income statement

See full
Revenue$1.7M-90.0%
Operating income-$98.4M+3.1%
Net income-$93.1M+6.0%
EPS (diluted)-$0.74+59.3%

Balance sheet

See full
Cash & equivalents$63.9M-50.3%
Total debt$35.7M+1,881%
Total equity$567.0M+237%
Total assets$671.6M+157%

Cash flow

See full
Operating cash flow-$87.1M-8.4%
CapEx$164.0K+343%
Free cash flow-$87.2M-8.5%

Valuation

See full
Market cap$3.52B+693%
Enterprise value$3.49B+955%
P/S418.8×

Profitability

See full
Operating margin-5,364%
Net margin-2,825.7%
FCF margin-4,487.4%

Returns & leverage

See full
Return on equity-64.6%
Debt / equity0.1×+0.1×
Current ratio7.5×+3.8×

Where this comes from

Reported directly by Alumis Inc. in its filing.

Tagged under the XBRL concept alms:AccruedResearchAndDevelopmentCurrent.

The source filing: Alumis Inc.’s 10-Q, filed May 14, 2026.

Filed
May 14, 2026, 4:16 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001847367-26-000010
(in thousands, except share and per share amounts)March 31, 2026December 31, 2025
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable$11,587$10,106
Research and development accrued expenses35,95934,781
Other accrued expenses and current liabilities12,58822,303
Deferred revenue, current6,3281,458
Operating lease liabilities, current4,4424,670
Total current liabilities70,90473,318

Item 1. Financial Statements (Unaudited)

FAQ

What is Alumis Inc.'s accrued research and development current?
Alumis Inc. (ALMS) reported accrued research and development current of $35.96M in Q1 2026.
How has Alumis Inc.'s accrued research and development current changed year-over-year?
Alumis Inc.'s accrued research and development current increased by 3.6% year-over-year, from $34.7M to $35.96M.
What is the long-term trend for Alumis Inc.'s accrued research and development current?
Over 2 years (2023 to 2025), Alumis Inc.'s accrued research and development current has grown at a 78.3% compound annual growth rate (CAGR), from $10.95M to $34.78M.
What does accrued research and development current mean?
This represents obligations for research and development services that have been performed by third parties but have not yet been invoiced or paid. It serves as a key indicator of the company's ongoing clinical trial activity and the associated financial liabilities incurred during the development process. Investors use this to gauge the true scale of R&D activity beyond what is reflected in cash payments.

Ask your AI about Alumis Inc.'s accrued research and development current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude